{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:06:46Z","timestamp":1770487606863,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T16:19:01Z","timestamp":1462465141000},"page":"472-476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-2176","authenticated-orcid":false,"given":"Alen","family":"Ostojic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dubravka","family":"Sertic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavle","family":"Roncevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Granic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolina","family":"Matic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Basic-Kinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranka","family":"Serventi-Seiwerth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-1641","authenticated-orcid":false,"given":"Ivo","family":"Radman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-0514","authenticated-orcid":false,"given":"Renata","family":"Zadro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damir","family":"Nemet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.04.003_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2016.04.003_bib2","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1186\/1752-1947-3-7112","article-title":"Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report","volume":"3","author":"Goubran","year":"2009","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.clml.2016.04.003_bib3","doi-asserted-by":"crossref","first-page":"9342","DOI":"10.1186\/1757-1626-2-9342","article-title":"Changing therapy from Glivec to a \u201ccopy\u201d imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports","volume":"2","author":"Asfour","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.clml.2016.04.003_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000319150","article-title":"Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report","volume":"3","author":"Chouffai","year":"2010","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clml.2016.04.003_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12185-009-0431-1","article-title":"Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase","volume":"91","author":"Mattar","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2016.04.003_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1309\/LMR1KA61JYKUXRDX","article-title":"Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia","volume":"41","author":"Razmkhah","year":"2010","journal-title":"Lab Med"},{"key":"10.1016\/j.clml.2016.04.003_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155214522143","article-title":"Clinical efficacy of generic imatinib","volume":"21","author":"de Lemos","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2016.04.003_bib8","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.003_bib9","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.003_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.04.003_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clml.2016.04.003_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.04.003_bib13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.04.003_bib14","series-title":"Ordinance Establishing the Criteria for Wholesale Pricing of Medicinal Products and the Method for Reporting Wholesale Prices","volume":"1801","author":"Republic of Croatia Ministry of Health","year":"2013"},{"key":"10.1016\/j.clml.2016.04.003_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/17474086.2014.966679","article-title":"Generics in chronic myeloid leukemia: current arguments for and against and the established evidence","volume":"7","author":"Soysal","year":"2014","journal-title":"Expert Rev Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016300465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016300465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:25Z","timestamp":1761870445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016300465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S2152265016300465"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.04.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}